Connection

Nathan Peiffer-Smadja to Lopinavir

Back to Details
This is a "connection" page, showing publications Nathan Peiffer-Smadja has written about Lopinavir.
Nathan Peiffer-Smadja
Connection Strength
0.079
Lopinavir
  1. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
    View in: PubMed
    Score: 0.079
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.